Jazz Pharmaceuticals Inc. reported net income above Wall Street’s expectations for the fourth quarter. Jazz Pharmaceuticals is a specialty pharmaceutical company, which is focused on developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.
Investing Insights: Warren Buffett Trashes Gold, But What About Silver?
Jazz Pharmaceuticals Earnings Cheat Sheet for the Fourth Quarter
Results: Net income for Jazz Pharmaceuticals Inc. rose to $37.5 million (88 cents per share) vs. $24.5 million (56 cents per share) in the same quarter a year earlier. This marks a rise of 53.2% from the year-earlier quarter.
Revenue: Rose 56.5% to $83.5 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Jazz Pharmaceuticals Inc. reported adjusted net income of $1.17 per share. By that measure, the company beat the mean estimate of $1.01 per share. It beat the average revenue estimate of $80.8 million.
Quoting Management: “2011 was an exceptional year, as our targeted investments in Xyrem continue to yield strong volume growth,” said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. “As we look ahead into 2012, the recent business combination broadens our product portfolio, further strengthens our team and provides an efficient platform for growth as we pursue our mission to improve patients’ lives.”
For the past five quarters, the company has seen double-digit year-over-year percentage revenue growth. Over that span, the company has averaged growth of 52.8%, with the biggest boost coming in the third quarter when revenue rose 63.8% from the year earlier quarter.
The company has now topped analyst estimates for the last four quarters. It beat the mark by 3 cents in the third quarter, by 6 cents in the second quarter, and by 3 cents in the first quarter.
Looking Forward: Over the past ninety days, the average estimate for the first quarter of the next fiscal year has fallen from 95 cents per share to 94 cents, indicating that analysts are growing pessisimistic about the company’s performance next quarter. The average estimate hasn’t changed from $3.16 per share for the fiscal year.
(Company fundamentals provided by Xignite Financials. Earnings estimates provided by Zacks)
Don’t Miss These Additional Hot Stories:
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com